Scientists have used a device that fits in the palm of the hand to sequence the human genome.
They say the feat, detailed in the journal Nature Biotechnology, opens up exciting possibilities for using genetics in routine medicine.
It is a far cry from the effort to sequence the first human genome which started in 1990.
The Human Genome Project took 13 years, laboratories around the world and hundreds of millions of dollars.
Since then there has been a revolution in cracking the code of life.
Prof Nicholas Loman, one of the researchers and from the University of Birmingham, We’ve gone from a situation where you can only do genome sequencing for a huge amount of money in well equipped labs to one where we can have genome sequencing literally in your pocket just like a mobile phone.
“That gives us a really exciting opportunity to start having genome sequencing as a routine tool, perhaps something people can do in their own home.”
Sequencing technology has the potential to change the way we do medicine.
Analysing the mutated DNA of cancers could be used to pick the best treatment. Or inspecting the genetic code of bacteria could spot antibiotic resistance early.
Prof Loman used the handheld device to track the spread of Ebola during the outbreak in West Africa.
The research group say the approach was around 99.5% accurate, but also allowed them to look at parts of human DNA that had been poorly studied.
The commonly used “short read” method of sequencing DNA involved breaking it up into short fragments, sequencing those and piecing it all back together like a jigsaw.
But the challenge is that some fragments of the genetic code look incredibly similar, so it becomes a near impossible puzzle made of identical pieces.
Prof Matthew Loose, from the University of Nottingham, UK, said the nanopore tech analysed longer strands of DNA so “we can read parts of the genome not seen before”.
This includes the tips of chromosomes – called telomeres.
Prof Loose told the BBC: “Telomere length can be quite important in cancer and ageing, it’s difficult in short reads because of the repeats, but we can see and start to map those things.”
But while the cost of the sequencing is tumbling, there remains a big barrier – being able to rapidly read the genetic code is not the same as understanding what it says.
“But short-term patient benefits also depend on how well and how fast we can analyse and make sense of the genomic data, and that is still quite a challenge.”